Weekly Research Analysts’ Ratings Changes for Intuitive Surgical (ISRG)

Several brokerages have updated their recommendations and price targets on shares of Intuitive Surgical (NASDAQ: ISRG) in the last few weeks:

• 7/30/2026 – Intuitive Surgical was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $391.00 price target on the stock.
• 7/28/2026 – Intuitive Surgical is now covered by UBS Group AG. They set a “neutral” rating and a $500.00 price target on the stock.
• 7/28/2026 – Intuitive Surgical was upgraded by BNP Paribas Exane to “outperform”.
• 7/28/2026 – Intuitive Surgical was downgraded by TD Cowen from “buy” to “hold”.
• 7/28/2026 – Intuitive Surgical was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $500.00 price target on the stock, down from $550.00.
• 7/27/2026 – Intuitive Surgical was given a new $357.44 price target by Piper Sandler.
• 7/20/2026 – Intuitive Surgical had its “outperform” rating reaffirmed by BMO Capital Markets.
• 7/17/2026 – Intuitive Surgical had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $483.00 price target on the stock, down from $577.00.
• 7/17/2026 – Intuitive Surgical had its “overweight” rating reaffirmed by Piper Sandler. They now have a $470.00 price target on the stock, down from $580.00.
• 7/17/2026 – Intuitive Surgical had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $487.00 price target on the stock, down from $654.00.
• 7/17/2026 – Intuitive Surgical had its price target lowered by JPMorgan Chase & Co. from $550.00 to $450.00. They now have an “overweight” rating on the stock.
• 7/17/2026 – Intuitive Surgical had its price target lowered by Stifel Nicolaus from $670.00 to $550.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Intuitive Surgical had its price target lowered by Citigroup Inc. from $590.00 to $500.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Intuitive Surgical had its price target lowered by BTIG Research from $512.00 to $469.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Intuitive Surgical had its price target lowered by Robert W. Baird from $525.00 to $500.00. They now have an “outperform” rating on the stock.
• 7/17/2026 – Intuitive Surgical had its price target lowered by Leerink Partners from $573.00 to $454.00. They now have an “outperform” rating on the stock.
• 7/17/2026 – Intuitive Surgical had its price target lowered by Sanford C. Bernstein from $750.00 to $685.00. They now have an “outperform” rating on the stock.
• 7/16/2026 – Intuitive Surgical had its price target lowered by Truist Financial Corporation from $580.00 to $510.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Intuitive Surgical was given a new $500.00 price target by Mizuho. They now have a “neutral” rating on the stock.
• 7/14/2026 – Intuitive Surgical was given a new $670.00 price target by Stifel Nicolaus.
• 7/13/2026 – Intuitive Surgical was given a new $512.00 price target by BTIG Research.
• 7/13/2026 – Intuitive Surgical had its price target lowered by TD Cowen from $585.00 to $520.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Intuitive Surgical had its price target lowered by Royal Bank Of Canada from $650.00 to $600.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Intuitive Surgical is now covered by BMO Capital Markets. They set an “outperform” rating and a $518.00 price target on the stock.
• 7/8/2026 – Intuitive Surgical had its “buy” rating reaffirmed by Citigroup Inc..
• 7/8/2026 – Intuitive Surgical was upgraded by BMO Capital Markets to “strong-buy”.
• 7/6/2026 – Intuitive Surgical was given a new $430.00 price target by Evercore Inc.
• 6/13/2026 – Intuitive Surgical was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/12/2026 – Intuitive Surgical had its price target lowered by Bank of America Corporation from $520.00 to $515.00.

Insider Activity

In other news, SVP Iman Jeddi sold 5,625 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the transaction, the senior vice president directly owned 6,463 shares of the company’s stock, valued at approximately $2,718,014.65. This trade represents a 46.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total transaction of $169,656.00. Following the completion of the sale, the executive vice president owned 5,720 shares of the company’s stock, valued at approximately $2,426,080.80. The trade was a 6.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,634 shares of company stock valued at $2,796,795 in the last quarter. Corporate insiders own 0.60% of the company’s stock.

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.